2025 年 11 月 27 日，清华大学 江鹏 课题组 （ 吴珺 、 李根 、 周嘉文 为论文共同第一作者） 在 Cell 子刊 Developmental Cell 上发表了题为： Vitamin B6 preserves the stemness-like phenotypes and antitumor ability of CD8 + T cells 的研究论文。 该研究揭示了饮食来源的代谢小分子 维生素 B6 能够促进肿瘤内浸润 CD8 + T 细胞 的干细胞样特征来增强 抗肿瘤免疫功能，并且表现出维生素 B6 在肿瘤免疫治疗中的临床应用潜力。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 肿瘤浸润淋巴细胞通常功能失调，但其通过尚不明确的机制表现出干细胞样行为。 肿瘤浸润淋巴细胞通常功能失调，但通过尚不明确的机制表现出干细胞样行为。在这项最新研究中，研究 团队发现，给予 维生素 B6 或其活性形式—— 磷酸吡哆醛 （PLP） ，能使小鼠和人类的 CD8 + T 细胞 具 备更强的持久性、干细胞样的表型以及清除肿瘤的能力。 通过吡哆醛激酶 （PDXK） 杂合性降低磷酸吡哆 醛 （PLP） 水平，会导致肿瘤 ...

Core Viewpoint - Excessive consumption of high oxalate foods like spinach can lead to secondary oxalate deposition nephropathy, with contributing factors including metabolic disorders and intestinal diseases [1] Group 1: Disease Mechanism and Types - Oxalate deposition nephropathy is characterized by the accumulation of oxalate crystals in the renal tubules and interstitium, resulting in kidney damage [2] - The disease can be classified into primary and secondary types, with secondary being more common and occurring at any age due to excessive oxalate intake and impaired excretion [2] Group 2: Dietary Factors and Risks - Foods high in oxalate include spinach, purslane, beet greens, nuts, chocolate, and tea, which can lead to the disease if consumed in excess [3] - Other factors such as excessive intake of oxalate precursors, dehydration, and lack of vitamin B6 can increase the risk of developing oxalate deposition nephropathy [3] Group 3: Prevention Strategies - Early detection of secondary oxalate deposition nephropathy can be achieved by testing urine oxalate levels, with a threshold of over 45 mg in 24 hours indicating high oxalate levels [4] - Prevention strategies include dietary modifications, such as reducing high oxalate food intake and ensuring adequate calcium and hydration to minimize oxalate absorption [5][6] - High-risk groups, including patients with chronic kidney disease and gastrointestinal disorders, should follow specific dietary guidelines and monitor their kidney function closely [6]

Group 1: Industry Performance - The chemical raw materials index increased by 0.40%, and the chemical machinery index rose by 1.28%, while the remaining five indices in the petroleum and chemical sectors declined [1] - The chemical pharmaceutical index decreased by 2.36%, and the pesticide and fertilizer index fell by 1.63% [1] - The petroleum processing index dropped by 0.20%, the petroleum extraction index remained stable, and the petroleum trade index decreased by 1.32% [1] Group 2: Commodity Prices - International crude oil prices saw a significant increase, with West Texas Intermediate crude oil futures settling at $65.72 per barrel, up 4.85% from September 19, and Brent crude oil futures at $70.13 per barrel, up 5.17% [1] - The top five rising petrochemical products included liquid chlorine up by 37.07%, paraquat mother liquid up by 6.25%, lithium battery electrolyte up by 5.71%, hydrogen peroxide up by 4.64%, and fluorite 97 wet powder up by 4.09% [1] - The top five declining petrochemical products included vitamin E down by 7.07%, sulfuric acid down by 6.54%, vitamin B6 down by 5.83%, methyl acrylate down by 5.59%, and dichloromethane down by 3.83% [1] Group 3: Capital Market Performance - The top five rising listed chemical companies were Lanfeng Biochemical up by 61.16%, Shuangwei New Materials up by 44.81%, Huarsoft Technology up by 31.83%, United Chemical up by 27.93%, and Asia-Pacific Industry up by 27.66% [2] - The top five declining listed chemical companies were Jinpu Titanium down by 23.15%, Hanwei Technology down by 18.80%, Sanwei Co. down by 14.29%, Hongda Co. down by 13.56%, and Bingyang Technology down by 11.93% [2]

Group 1 - The core point of the announcement is the successful convening of the third extraordinary general meeting of shareholders of Hubei Guangji Pharmaceutical Co., Ltd., where all proposals were approved without any objections [1][2]. - The meeting was held on September 18, 2025, with a combination of on-site and online voting, ensuring broad participation from shareholders [3][5][6]. - A total of 87 participants representing 104,743,265 shares attended the meeting, accounting for 30.2071% of the total shares of the company [8]. Group 2 - The meeting approved three key proposals: the change of registered capital and revision of the company's articles of association, the revision of the rules for shareholder meetings, and the revision of the rules for board meetings [10][11][14]. - The voting results for the proposal on changing registered capital showed 99.3705% approval from the attending shareholders, with only 0.6152% opposed [10]. - The legal opinion provided by Hubei Zhongqin Law Firm confirmed that the meeting's procedures and resolutions were in compliance with relevant laws and regulations, validating the legality of the decisions made [18]. Group 3 - Hubei Guangji Pharmaceutical Co., Ltd. announced the receipt of a re-registration approval notice for the chemical raw material drug Vitamin B6 from the Hubei Provincial Drug Administration [21]. - The re-registration ensures the stability and continuity of the production and sales qualifications for Vitamin B6, which is used in the production of Vitamin B6 tablets and injections [21][22]. - The approval notice is valid until September 16, 2030, indicating a long-term assurance for the company's operations in this segment [21].

Core Viewpoint - Guangji Pharmaceutical announced that its subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., has received approval from the Hubei Provincial Drug Administration for the re-registration of its chemical raw material, Vitamin B6 [1] Group 1 - The approval is documented in the "Chemical Raw Material Re-registration Approval Notice" issued by the regulatory authority [1]

Core Viewpoint - Guangji Pharmaceutical announced that its subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., has received the approval from the Hubei Provincial Drug Administration for the re-registration of the chemical raw material Vitamin B6 [1] Group 1 - The approval includes a notification for the chemical raw material Vitamin B6, which is used in the production of Vitamin B6 tablets and injections [1]

Group 1 - Dongli Machinery participated in the 2025 China Automobile Off-Road Rally Championship and won the T2.3 group championship as a club team [1] - The Arnoda-Black Bear Tire Chery Racing Team secured the T1.1 group championship [1] - Great Wall Haval Team, using Dongli Machinery's "Taihang Water" brand shock absorbers, achieved victories in the T2.1 and T2.E groups [1] Group 2 - Guangji Pharmaceutical's subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., received approval from the Hubei Provincial Drug Administration for the re-registration of the chemical raw material drug Vitamin B6 [1] - The raw material is intended for the production of Vitamin B6 tablets and Vitamin B6 injections [1]

Group 1 - Dongli Machinery participated in the 2025 China Automobile Off-Road Rally Championship and won the T2.3 group championship as a club team [1] - The Arnoda-Black Bear Tire Chery Racing Team secured the T1.1 group championship [1] - Great Wall Haval Team, using Dongli Machinery's "Taihang Water" brand shock absorbers, won championships in the T2.1 and T2.E groups with a total of five vehicles [1] Group 2 - Guangji Pharmaceutical's subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., received approval from the Hubei Provincial Drug Administration for the re-registration of the chemical raw material drug Vitamin B6 [1] - The raw material is intended for the production of Vitamin B6 tablets and Vitamin B6 injection solutions [1]

Group 1 - The core point of the article is that Guangji Pharmaceutical's subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., has received approval for the re-registration of its chemical raw material Vitamin B6 from the Hubei Provincial Drug Administration, ensuring the stability and continuity of its production and sales qualifications [1] Group 2 - Vitamin B6 is used as a raw material for the production of Vitamin B6 tablets and injections, indicating its importance in the pharmaceutical industry [1] - The approval of the re-registration certificate is crucial for maintaining the company's operational capabilities in the Vitamin B6 market [1]

Group 1 - The core point of the article is that Guangji Pharmaceutical (000952.SZ) announced that its subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., received the approval notice for the re-registration of the chemical raw material Vitamin B6 from the Hubei Provincial Drug Administration [1] - The approval ensures the stability and continuity of the production and sales qualifications for Vitamin B6, which is used in the production of Vitamin B6 tablets and injections [1]